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Chlamydia trachomatis is the most important infectious cause of infertility in women with
important implications in public health and for which a vaccine is urgently needed. Recent
immunoproteomic vaccine studies found that four polymorphic membrane proteins (PmpE,
PmpF, PmpG and PmpH) are immunodominant, recognized by various MHC class II haplo-
types and protective in mouse models. In the present study, we aimed to evaluate genetic
and protein features of Pmps (focusing on the N-terminal 600 amino acids where MHC
class II epitopes were mapped) in order to understand antigen variation that may emerge
following vaccine induced immune selection. We used several bioinformatics platforms to
study: i) Pmps’ phylogeny and genetic polymorphism; ii) the location and distribution of pro-
tein features (GGA(I, L)/FxxN motifs and cysteine residues) that may impact pathogen-host
interactions and protein conformation; and iii) the existence of phase variation mechanisms
that may impact Pmps’ expression. We used a well-characterized collection of 53 fully-
sequenced strains that represent the C. trachomatis serovars associated with the three dis-
ease groups: ocular (N=8), epithelial-genital (N=25) and lymphogranuloma venereum
(LGV) (N=20). We observed that PmpF and PmpE are highly polymorphic between LGV
and epithelial-genital strains, and also within populations of the latter. We also found hetero-
geneous representation among strains for GGA(I, L)/FxxN motifs and cysteine residues,
suggesting possible alterations in adhesion properties, tissue specificity and immunogenic-
ity. PmpG and, to a lesser extent, PmpH revealed low polymorphism and high conservation
of protein features among the genital strains (including the LGV group). Uniquely among the
four Pmps, pmpG has regulatory sequences suggestive of phase variation. In aggregate,
the results suggest that PmpG may be the lead vaccine candidate because of sequence
conservation but may need to be paired with another protective antigen (like PmpH) in order
to prevent immune selection of phase variants.
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Introduction
Chlamydia trachomatis is an obligate intracellular human bacterial pathogen, comprised of 15
to 18 major serovars. Serovars A-C are responsible for ocular infections that result in trachoma
[1]. Serovars D-K cause sexually transmitted diseases such as cervicitis and pelvic inflamma-
tory disease (PID), and globally are an important infectious cause of infertility and ectopic
pregnancy in women [2]. Serovars L1-L3 also enter through the ano-urogenital tract, but may
dissiminate via infection of macrophages to regional draining lymph nodes, causing lympho-
granuloma venereum (LGV) [3]. C. trachomatis is the major bacterial cause of sexually trans-
mitted infections (STIs), accounting for ~106 million of the 500 million new cases of STIs that
occur each year worldwide [4]. In Europe, almost half of the estimated 47 million STI cases are
due to C. trachomatis [4], while nearly 1.4 million infections are reported each year in the
United States [5]. Although the estimated global economic burden is uncalculated, over $516
million are spent annually in direct medical costs on genital chlamydial infections in the United
States, making C. trachomatis the most costly infection among the nonviral STIs [6–7].
Despite screening and treatment public health programs to control Chlamydia, the inci-
dence of C. trachomatis infection has increased [4, 8–10]. Thus, there is an urgent need for an
efficacious vaccine that prevents acquisition and transmission of infection and the develop-
ment of pelvic inflammatory disease sequelae. Cumulative studies in animal models and
human infections [8, 11–23] have shown that systemic and mucosal CD4 T cell-mediated
immunity is necessary for protection against C. trachomatis infection. Among antigen candi-
dates that have been studied [11, 15, 24], members of the polymorphic membrane protein fam-
ily (PmpA-I) have shown promise as vaccine components as they are dominant antigenic
targets for cellular immune responses [25–29]. Four of the nine Pmps (PmpE, PmpF, PmpG
and PmpH) have been identified via immunoproteomics as dominant T-cell antigens with
multiple MHC class II binding peptides for both C. trachomatis and C.muridarum and
observed to be protective in the murine genital tract infection model [25, 28–30]. The fact that
each Pmp generates different peptides recognized by different MHC class II haplotypes confers
on them the capability of immunizing outbred populations [25]. In the murine model, a PmpG
epitope was found to persist on splenic antigen presenting cells for at least 6 months [26]. Tet-
ramer staining also demonstrated PmpG as one of the quantitatively dominant antigens recog-
nized by murine CD4 T cells [17].
Pmps are Chlamydia-specific outer membrane proteins whose precise functions remain
unknown, but which have been implicated in pathogenesis and host cell adherence. As typical
type V autotransporters [31–32], Pmps are capable of translocating to the bacterial surface
their N-terminal Sec-dependent leader sequence (passenger domain), containing multiple
short repetitive motifs (GGA(I, L, V) and FxxN) [33]. The proteins may also undergo complex
infection-dependent post-translational proteolytic processing [34–37]. These proteins mediate
in vitro chlamydial attachment to human epithelial and endothelial cells [34, 38]. Previous bio-
informatics analyses suggested that six of the 9 pmps are under positive selection either driving
bacterial adaptation to specific niches (ocular conjunctiva, epithelial-genitalia and lymph
nodes), or during a strains’ diversification within a particular niche [39]. Numerous mutations
within bioinformatically predicted HLA class I and II T-cell epitopes for the N-terminal
domain for one Pmp (PmpF) have already been identified [40]. Pmps were also found in tissue
culture to be variably expressed at the chlamydial cell surface, where each protein seemed sub-
jected to an independent high-frequency on/off switching at the inclusion level [41].
Therefore we aimed to bioinformatically assess the allelic and phase variation of these anti-
gens, in particular for the four most promising vaccine candidates PmpE, PmpF, PmpG and
PmpH, in order to understand if putative antigenic escape variants may emerge following
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vaccination. We performed a detailed bioinformatic analysis using a well-characterized collec-
tion of 53 strains whose genomes have been fully sequenced [42–43] and which represent C.
trachomatis serovars associated with the three canonical disease groups: ocular, epithelial-
genital and LGV. By encompassing strains from temporally and geographically diverse sources
around the world, this collection should capture C. trachomatis genetic diversity. Overall, we
analyzed 25 strains from epithelial-genital serovars, 20 strains from LGV serovars, and eight
strains from ocular serovars.
Materials and Methods
Genetic and phylogenetic analyses
In order to assess the genetic variability of PmpE, PmpF, PmpG and PmpH within C. tracho-
matis, 53 genome sequences representative of distinct or same-serovar strains were retrieved
from GenBank and aligned using the progressiveMauve algorithm of Mauve 2.3.1 [44] with the
default parameters and an initial match seed weight appropriate for 1MB genomes. Basically,
Progressive Mauve performs a recursive anchor search and a full gapped anchored alignment
of the genome sequences using a modified MUSCLE algorithm. For all pmps, individual align-
ments were extracted from the whole-genome alignment, and visually inspected with MEGA6
software (http://www.megasoftware.net) for further correction.
For each pmp, MEGA6 was also used to estimate the number of gene variable sites and to
compute overall mean distances and matrices of pairwise comparisons at both nucleotide and
protein level, based on the number of differences and p-distance value (that calibrates the
obtained differences relative to the total number of sites under comparison) among the 53
strains, along with the respective standard error estimates (bootstrap = 1000). Evaluation of
variable sites and mean genetic distances was also performed within and between the three dis-
ease groups. We also evaluated the impact of the genetic heterogeneity of each group of strains
in the overall polymorphism of each pmp, through a sliding-window analysis using the DNA
polymorphism tool of the DnaSP software, version 5 [45], with a window size and step size of
15.
Phylogenetic relationships among strains were inferred with MEGA 6, by using the Neigh-
bor-Joining method [46] in conjunction with a bootstrap re-sampling strategy (1000 repli-
cates), as previously described [47]. Evolutionary nucleotide distances were estimated with the
Kimura 2-parameter (K2P) model [48] that takes into account transitional and transversional
substitution rates, while assuming identical nucleotide frequencies and invariable substitution
rates among sites [49]. At the protein level, evolutionary distances were computed based on the
number of differences. Because of the different lengths of the sequences, the pairwise-deletion
option was chosen to remove all sites containing missing data or alignment gaps from all dis-
tance estimations, only when the need arose and not prior to the analysis.
In order to identify specific regions that most contribute to the phylogenetic segregation of
taxa within each Pmp, we evaluated the similarity both among the 53 strains and between dis-
ease groups. Briefly, SimPlot 3.5.1 software [50] was used to plot a codon-based nucleotide sim-
ilarity score of each strain against a particular query by estimating pairwise distances with K2P
model, without excluding gaps among sequences and considering a transition-transversion
substitution rate of 2. The similarity estimations were performed in a sliding window size that
ranged from 40 bp for pmpG to 80 bp for pmpF (adjusted according to polymorphism degree),
moved across the alignment in a step size of 3 bp. In parallel, SWAAP 1.0.3 software [51] was
used to compute the percentage of amino acid (a.a) identity among each pair of sequences
throughout all Pmps, over a sliding window that ranged from 20 a.a for both PmpG and PmpH
to 40 a.a for PmpF, and a step size of 3 a.a.
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These analyses were also performed using gene segments encoding the first ~600 amino
acids of each Pmp, as they are part of the surface exposed passenger domain where all MHC
class II binding peptides were experimentally mapped [25] (see Results and Discussion
section).
Analysis of protein features
Pmps are predicted to have adhesin functions [34, 38, 52]. By using the SeqBuilder module of
LaserGene (DNASTAR) we therefore assessed the differential presence among all 53 strains of
the repetitive GGA(I, L, V) and FxxN motifs as well as of cysteine residues in each Pmp. More-
over, to shed light on the putative impact of Pmps’ variability on surface probability and immu-
nogenicity, we used the Protean program (DNASTAR) to perform a comparative analysis of
the protein sequences. While the surface probability parameter predicts the likelihood of a
given region lying on the surface of a protein using the approach of Emini et al. [53], the analy-
sis of immunogenicity uses the approach of Jameson and Wolf [54] that combines several
methods for protein structural features (like hydrophilicity, surface probability, flexibility and
secondary structure) to predict potential antigenic determinants. For both analyses, the default
parameters of each method were used, with surface regions predicted by forming the product
of residue specific surface propensities over a range of 5 amino acids and based on a surface
decision threshold>1. In order to facilitate the latter analyses, we used one strain representa-
tive of the main branches of the respective tree generated with the 53 fully-sequenced genomes,
as these strains accurately represent the Pmp genetic backbone of the remainder same-branch
taxa. The ocular strain A/Har13, the two epithelial-genital strains D/UW3 and E/150, and the
LGV strain L2b/UCH1 were selected as they were among the strains found to be commonly
present in the different main branches of all phylogenetic trees. Considering that some Pmps
have an additional divergent branch containing genital strains, we opted for including an extra
epithelial-genital strain to increase the confidence of the analysis. Thus, the strain G/11074 was
also used for the analysis of both PmpH and PmpG, while the strains G/11222 and E/SW2
were used for the analysis of PmpF and PmpE, respectively. After performing preliminary data,
we observed that including other strains besides these ones, did not alter the final output. In
order to increase the probability of observing relevant disparities among strains for surface
probability and immunogenicity, we specially focused on regions falling below a similarity cut-
off of 85% (based on SWAAP plots).
Analysis of phase variation
Analysis of phase variation was performed by using different approaches by considering several
genetic features known to underlie phase variation mechanisms, such as short sequence repeats
(homopolymeric and non-homopolymeric tracts), IS-like sequences, frameshift mutations,
small indels, hairpin structures, RNase E cleavage sites, and promoter sequences [55–57]. First,
we checked the differential presence of homopolymeric tracts and small indels among all 53
strains by using SeqBuilder (DNASTAR). For each operon, in silico promoter predictions were
made by using both the Neural Network Promoter Prediction (NNPP, http://www.fruitfly.org/
seq_tools/promoter.html) and the BPROM software (Softberry, http://linux1.softberry.com/
berry.phtml?topic = bprom&group = programs&subgroup = gfindb), to find elements resem-
bling putative σ66, σ28 and/or σ54 promoter sequences that may be differentially present among
strains, and thus used as fine-tune transcriptional pmp regulators. Moreover, several putative
regulatory elements that are known to affect transcription or translation were also searched
throughout each pmp operon and associated regulatory regions using SeqBuilder (DNASTAR).
Briefly, the differential existence of putative consensus cleavage sites for RNase E was examined
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among strains [58–60]. RNaseE is the major endonuclease that generally initiates mRNA deg-
radation in most bacteria [61]. We also searched for the presence of putative Shine-Dalgarno
ribosome binding sequences (RBS) [62] and previously described chlamydial RBS [63–66].
Results and Discussion
Global polymorphism analysis
In view of Chlamydiae’s reductive evolution, it is remarkable that the pmps vary in number
across species and encompass a sizeable chromosome portion (3–5%) [67]. For instance, over
13% of the C. trachomatis specific coding capacity is restricted to this gene family [68]. The
evaluation of the mean genetic distances among all 53 strains revealed that pmpF was the most
polymorphic pmp gene exhibiting the highest mean nucleotide substitution (214.3 (SE 8.9))
and also the highest p-distance value (0.0691 (SE 0.0029)), which corresponded to a mean of
72.4 (SE 5.0) (7.0%) amino acid substitutions. This degree of polymorphism is followed by
pmpH and pmpE with an overall nucleotide variability of 3.6% and 2.4%, respectively. pmpG
was observed to be the least variable gene with a polymorphism 6.9-fold lower than that of
pmpF. In fact, pmpG exhibited a mean of nucleotide substitutions among all 53 strains of 31.1
(SE 3.7) (1.0%), corresponding to a mean of 13.5 (SE 2.6) (1.3%) amino acid alterations. The
high variability shown by some Pmps accords with a recent analysis encompassing ~98% of the
C. trachomatis core genome [69] which placed pmpF, pmpE and pmpH within the top 20 most
polymorphic chromosomal genes. The set of polymorphic genes includes other important anti-
gens-coding genes, such as CT681/ompA and the paralogously related pmps CT049-CT051
[70–72]. Considering Pmps’ outer membrane localization and putative dual function in adhe-
sion and pathogenesis, the high polymorphism is expected to promote multiple antigenic and/
or adherence phenotypes that may influence strains’ pathogenic diversity and tissue specificity.
By performing a polymorphism sliding-window analysis throughout each gene (Fig 1), we
observed that most of the genetic variability in pmpE is concentrated into the mid-region of the
gene (~1050–2100 bp), while a greater nucleotide substitution density is seen within the first
two-thirds of pmpF. In contrast, for both pmpG and pmpH, the overall variability appears to be
homogeneously distributed throughout each gene, although a polymorphism peak is seen
around position 350 for pmpG (corresponding to three amino acids that are specific of LGV
strains) We also found distinct scenarios among the four pmps by evaluating the contribution
of the different disease groups to the overall species polymorphism (Fig 1). For both pmpF and
pmpH, the three disease groups seem to contribute to C. trachomatis diversity, as seen by the
successive increase in the overall genetic variability after the independent addition of either
LGV or ocular strains to the group of epithelial-genital strains. In fact, the number of variant
sites found among epithelial-genital strains augmented ~3-fold for pmpF and ~6-fold for
pmpH with addition of LGV strains, and an increase of 1.5-fold was seen after the subsequent
inclusion of ocular strains for both genes. For pmpE, the overall species polymorphism is essen-
tially provided by the genetic heterogeneity among the epithelial-genital strains, which harbor
almost 85% of the total 187 variant sites found. The dissimilar mutational pattern observed for
each pmpmay imply differences in how each Pmp fulfills adhesive and antigenic functions in
specific niches. Distinct regions were previously identified within pmpE, pmpF and pmpH,
where clusters of mutations were found, and were associated with strains’ clustering by cell-
tropism or ecological success [73]. In support of this notion, these four pmps were found to be
differently targeted by positive selection in each niche, being potentially involved in one or
more adaptive processes [39]. For instance, based on bioinformatic predictions that rely essen-
tially on the distribution and exclusive character of nonsilent changes, pmpF is identified to
encode specific cell tropism to both the ocular epithelium and mononuclear phagocytes.
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Besides niche-specific adaptation, some of the pmps were also predicted to evolutionarily
impact strains’ niche-specific pathogenicity, as the case of pmpG and pmpH, which appear to
contribute to the pathogenic diversity among LGV-causing strains [39]. Both pmpG and pmpH
have over-accumulated nonsynonymous substitutions (about 4-fold more frequent than silent
mutations) that result in protein variation among LGV strains [74]. Multiple factors may con-
tribute to the genetic diversity of pmps, such as recombinational hotspots involving this large
family of paralogous genes since multiple recombination hotspots have been identified
throughout the genome [43, 75]. Overall, these data suggest the existence of variant tissue-
specific host-interaction motifs that involve different Pmps.
Genetic and phylogenetic analyses of Pmps’ N-terminal 600 amino acid
domains
Previous immunoproteomic studies using the murine genital infection model [25] revealed
that PmpE, PmpF, PmpG and PmpH contain different MHC class II binding peptides in the
N-terminal half for both C.muridarum and C. trachomatis serovar D with between one and
three different peptides perMHC allele. Therefore, after an initial genetic analysis of the overall
Fig 1. Global polymorphism analysis. A) Sliding-window analysis of the genetic variability throughout each pmp (window and step size of 15 bp). For each
pmp, the black plot represents the polymorphism among all strain collection, while the remainder plots represent the impact of removing strains from the
ocular group (red plot) and from the LGV group (magenta plot) on the global polymorphism. The region highlighted in yellow encompasses the 1st 600 amino
acids (used in vaccine attempts) where further analyses were performed. The horizontal bars below the plots represent the typical domains of these
autotransporter proteins: passenger domain (magenta), middle domain (green), and C-terminal autotransporter domain (blue). B) Impact in both the number
and percentage of variable sites found among C. trachomatis strains after the successive addition of LGV and ocular strains to the epithelial-genital group.
doi:10.1371/journal.pone.0131695.g001
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polymorphism for the entire genes, the subsequent analyses (genetic, phylogenetic, and study
of protein features) were restricted to gene segments encoding the 1st ~600 amino acids of each
Pmp that encompass both the surface exposed passenger and middle domains (Fig 1) where all
MHC class II-bound peptides were experimentally mapped [25]. The selected gene segments
harbor almost 75% of all variant sites estimated for the whole pmpF and pmpE genes and at
least 50% of the variant sites for pmpG and pmpH.
The phylogenetic reconstructions based on the first 600 amino acids of each Pmp (S1 Fig),
mirror the tree topologies for the whole proteins (S2 Fig) and support the correlation between
pmp polymorphism and a strains’ phenotypic association with disease state. For instance, a
perfect segregation of strains by full-tropism was observed for PmpH, with strains representa-
tive of the three disease groups appearing clustered in distinct separated clades. For all Pmps,
the analysis of the matrices of pairwise distances revealed a low heterogeneity within both ocu-
lar and LGV strains (Table 1). In contrast, the average evolutionary divergence among the epi-
thelial-genital group varies among Pmps, with PmpE and PmpF exhibiting the highest
divergence, 14.5 a.a (SE 2.0) and 14.0 (SE 2.3), respectively, while PmpG and PmpH are much
less polymorphic, displaying a polymorphism 7- to 9-fold lower. However, if LGV strains are
included in a global group of genital strains, the average amino acid distances increases as epi-
thelial-genital strains are highly dissimilar from LGV strains for some Pmps (Table 1). Overall,
these results show that the 1st 600 a.a of PmpG is highly conserved in this 53 strain collection,
even among all genital strains (epithelial-genital and LGV), for which the observed mean
amino acid distances are about 2-, 3- and 7-fold lower than those seen for PmpH, PmpE and
PmpF, respectively. Of note, the segment of the 1st 600 a.a of PmpH is also highly conserved if
one considers solely epithelial-genital strains, where no more than 2 a.a differences are seen.
Analysis of peptide features
A hallmark of the chlamydial Pmp family is the presence of multiple repeats of the tetrapeptide
motifs GGA(I, L, V) and FxxN in their N-terminal half. The repetition of these motifs is seen
in very few non-chlamydial proteins, and has been suggested to be directly involved in adher-
ence processes [33, 76]. Thus, considering that Pmps likely have adhesive functions [34, 38]
and were found to be variably expressed at the chlamydial surface in vitro [41], we mapped the
location and determined the number of the GGA(I, L, V) and FxxN as well as of the cysteine
residues within the 1st 600 a.a of each Pmp for all 53 strains (Fig 2). We observed that the FxxN
motif occurs on average 12.3-times per Pmp, being ~2-fold more frequent than GGAI motifs,
Table 1. Mean amino acid distances within the 1st 600 amino acids of each Pmp.
PmpE PmpF PmpG PmpH
No. diff. SE No. diff. SE No. diff. SE No. diff. SE
Overall mean 28,0 3,4 53,2 4,4 7,7 1,8 20,9 2,7
Within Groups
Ocular 1,9 0,8 1,0 0,5 0,8 0,4 0,0 0,0
Epithelial-genital 14,5 2,0 14,0 2,3 1,7 0,9 2,0 0,8
LGV 0,0 0,0 0,0 0,0 0,6 0,3 0,8 0,4
Genital (with LGV) 19,5 2,5 52,2 4,7 7,4 1,8 16,9 2,7
Between Groups
Ocular / Epithelial-genital 39,2 5,3 65,5 6,9 3,4 1,4 29,9 5,0
Ocular / LGV 47,4 6,3 111,0 8,9 11,6 3,1 45,5 6,3
Epithelial-genital / LGV 19,0 3,1 84,0 7,8 12,0 3,2 31,0 5,0
doi:10.1371/journal.pone.0131695.t001
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which appear on average 5.8-times per Pmp. The mean incidence of FxxN in the remaining
C. trachomatis proteome was shown to be 0.73 per protein, whereas GGAI is predicted to be
present as single copy in only 10 other Chlamydia proteins [33]. No GGA(I, L, V) or FxxN
motif is found outside the 1st 600 a.a for each Pmp, which is consistent with the exclusive pres-
ence of adhesion domains in protein regions that interact with the host. The number of con-
served GGAIs varied among the four Pmps, ranging from two for PmpH to eight for PmpE.
All Pmps displayed 11 conserved FxxN motifs; one of these fell within the MHC class II (I-Ab)-
bound C. trachomatis serovar D-derived peptide (AMANEAPIAFIANVAG) (Fig 3) recently
identified in PmpG [25].
The distribution of the two types of peptide motifs is nonrandom, being mainly clustered
within a discrete region that spans between ~220 a.a for PmpH to ~280 a.a for PmpF (Fig 2).
Most of these motifs appear as doublets of FxxN-x2-25-FxxN and FxxN-x4-20-GGAI, whose dif-
ferential occurrence, number and spacing vary both among Pmps and among different groups
of strains for the same Pmp. They were also found to be in close proximity or adjacent to cyste-
ine residues. The number of conserved cysteines ranges from eight for PmpG to 12 for PmpE.
Considering that cysteines are known to play an important role in maintaining structural
motifs, such GGAI/FxxN nonrandom distribution and possible cooperative action with the
cysteine residues may yield unique structural or functional constraints for interaction with the
host cell.
We also observed that the majority of the tetrapeptide motifs occurred in close proximity or
fall within regions containing SNPs differentiating specific groups of strains (Fig 3), which may
widen adhesion or immunogenic differences within each Pmp, as described for the major chla-
mydial membrane protein MOMP [77–79]. In support of this, a typical conserved FxxN-X5-
GGAI doublet was found to overlap the MHC class II (I-Ab)-bound peptide (AEKGG-
GAIYAPTIDISTNGGS) identified in PmpH [25], which is conserved solely among ocular and
epithelial-genital strains (Fig 3). This epitope is also in very close proximity to another con-
served FxxN-X4-GGAI doublet and a conserved cysteine residue. Based on bioinformatic pre-
dictions, none of the three MHC class II (I-Ab)-bound C. trachomatis serovar D-derived
peptides recently identified in PmpE, PmpG and PmpH [25] fall in regions that impact vari-
ability in immunogenicity and surface exposure of the respective proteins (S3 Fig). Although
the precise function of the tetrapeptide motifs is yet unknown, it has been shown by using dele-
tion analysis that Pmps’ adhesion capability requires at least the presence of one of these dou-
blets [80]. Also, each Pmp was shown to exhibit in vitro a distinctive adhesion profile
Fig 2. Distribution of FxxNmotifs (purple), GGA(I, L) motifs (orange), and cysteine residues (black) within the 1st 600 a.a (limited by the vertical
dashed line) of each Pmp. Asterisks indicate motifs nonconserved among all 53 strains.
doi:10.1371/journal.pone.0131695.g002
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depending on the human cell type (epithelial versus endothelial) [34]. The mutational pattern
of PmpE, PmpF, PmpG and PmpH was shown to be associated with high efficiency of in vitro
attachment to host cells [81]. It has been hypothesized that these short repetitive motifs may be
involved in maintaining the Pmp conformation that promotes adhesion, and/or might directly
mediate interaction with human receptors [80]. Therefore, the wide variation of these repetitive
motifs seen among intra- and inter-Pmps (Figs 2 and 3), is consistent with a role in the forma-
tion of niche-specific binding “receptors” for host-interaction.
Analysis of phase variation
Since pmps have been suggested to undergo phase variation-like mechanisms to promote mul-
tiple antigenic and/or adherence phenotypes [41], we searched for putative phase variation fea-
tures on each gene [55–57]. In distinction to pmpE, pmpF and pmpH that reveal no poly(C) or
poly(G) stretches, pmpG exhibits an in-frame poly(G) tract of nine residues for all non-LGV
strains and eight residues for LGV strains (data not shown). This mirrors that found for C.
pneumoniae pmpG family [33, 82–84], suggesting that slipped-strand phase variation [55, 57]
may be a common phenotype for PmpG. However, it is not known if the observed poly(G)
tract influences pmpG expression in C. trachomatis. Although all annotated genome sequences
appear to possess a functional PmpG, we cannot be certain that C. trachomatis strains only har-
bor in-frame poly(G) tract in pmpG. In fact, it is known that this type of regions may yield
biased data in some Next Generation Sequencing. So, it is possible that strains with dissimilar
number of “G” (or even a mixture of clones showing different number of “G”) have not been
properly annotated. Nevertheless, as only PmpG shows a poly-G tract, which may be involved
Fig 3. Pmp alignments showing examples of protein regions containing high concentration of FxxNmotifs (purple), GGA(I, L) motifs (orange), and
cysteine residues (blue).MHC class II (I-Ab)-bound C. trachomatis peptides are highlighted in yellow.
doi:10.1371/journal.pone.0131695.g003
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in phase variation, and because its sequence is highly conserved among all genital strains
(including LGV strains), this may be its major mechanism of antigen or niche variation. We
also found a non-homopolymeric repetitive motif “PAPAPAPA” in PmpH for some epithelial-
genital strains, which is shorter for other epithelial-genital strains and absent for both the LGV
and ocular groups (data not shown). A Blast search for this motif was not informative about its
putative role, as it seems to be commonly present in diverse proteins, such as regulatory pro-
teins, acid-shock proteins and acetyl-CoA carboxylases, from different species. Hypothetically
this genetic feature could be associated with phase variation and would exclusively impact
PmpH immunogenicity of epithelial-genital strains. Although this hypothesis is speculative, if
PmpH is used as a vaccine component, the use of peptides encompassing all “PA” combina-
tions may be prudent.
It is known that the insertion-excision of mobile elements (like IS-elements) may also
impact gene expression [55], and the presence of putative remnants of IS-like elements flanked
by direct target repeats has already been described for both pmpB and pmpC [73]. However, no
such elements were found in the four pmps under evaluation.
Past studies have shown that expression regulation of C. trachomatis genes is controlled at
both transcriptional and translational levels, thus involving multiple complex aspects, like
DNA supercoiling, heterogeneity within promoter sequences, cis- and trans-regulatory ele-
ments, and mRNA stability. It is known that various chlamydial genes are regulated by two or
three different promoters, often with multiple σ factor binding (σ66, σ28 and/or σ54) [85]. We
found putative σ66 promoters within both pmpFE and pmpGH regulatory regions by using in
silico predictions (S1 and S2 Tables), but no elements resembling a σ28 or σ54 promoter
sequence. In distinction to pmpFE, the most promoter predicted for the pmpGH operon con-
tains a transcritptional start site (TSS) that has already been experimentally identified for the
L2b/UCH1 strain [86], and it reveals a variable site in the -35 element that distinguishes LGV
from epithelial-genital strains. Some variable nucleotide sites are also seen near the -10 ele-
ments, the TSSs, or A/T spacer, and several putative consensus RNase E cleavage sites were
found throughout both operons and their regulatory regions. The polymorphisms found close
or inside Shine-Dalgarno regulatory elements and the nonconservation of RNase E cleavge
sites, may suggest heterogeneous expression among strains for both pmpFE and pmpGH oper-
ons, supporting previous experimental findings showing Pmp expression differences not only
between L2 and E strains, but also within same-serovar strains [87].
Conclusions
Recent vaccine studies in the murine model [29, 88] provided evidence that a vaccine com-
posed of PmpEFGH plus MOMP formulated with a Th1 polarizing adjuvant, was more immu-
nogenic and cleared infection faster than a single antigen vaccine. The suitability of a Pmp-
based vaccine will be influenced by antigenic variability displayed during infection of the geni-
tal tract. The in silico predictions from the present study suggest that PmpF and PmpE may be
less reliable antigens for vaccine purposes due to high sequence polymorphism. This polymor-
phism, together with putative alterations in structural constraints provided by heterogenity
among strains in GGA(I, L)/FxxN motifs and cysteine residues, also suggest a possible role in
immunogenicity variability. By contrast, the low polymorphism and high conservation of pro-
tein features for PmpG and to a lesser extent for PmpH, suggest that these proteins may be bet-
ter vaccine candidates. Since phase variation may impact PmpG expression a single-
component PmpG subunit vaccine may not provide protection against infection due to phase
variation. Based on bioinformatics analysis we suggest that pairing of PmpG with PmpH could
be a viable approach, in order to provide a range of epitopes for CD4+ T cell recognition
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among different MHC genetic backgrounds and to provide cross-protection against multiple
antigenic variants of C. trachomatis.
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